Baylor College of Medicine’s Cancer Genetics Laboratory will launch a sequencing-based test on the Ion Torrent PGM that uses the firm’s Ion AmpliSeq Cancer Panel to target mutations in 46 cancer genes, according to an article on GenomeWeb.com.
The lab is among the first in the country to use targeted next-gen sequencing in a clinical setting for cancer. The test, which the CLIA- and CAP-certified CGL will start offering in December, targets 739 mutations in 46 commonly mutated cancer genes. It will be priced under $2,000 and its turnaround time will be around 7 to 10 days.
While Baylor will offer the test on a research basis, it can be ordered by both basic researchers and doctors.
For more information, read the original article here.
Source: Genome Web